Harmony Biosciences Holdings, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Harmony Biosciences Holdings, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Harmony Biosciences Holdings, Inc. do? Business model and key facts
Get the full picture of Harmony Biosciences Holdings, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 293
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Stocks related to Harmony Biosciences Holdings, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Harmony Biosciences Holdings, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Harmony Biosciences Holdings, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
